In the healthy brain, APOE is mainly produced by astrocytes, but in Alzheimer's disease (AD), reactive microglia greatly increase APOE expression. APOE from microglia binds to TREM2 on their surface in pathological conditions, regulating their response to Aβ and tau pathology. This interaction influences microglial migration to Aβ plaques, phagocytosis, and inflammation, affecting AD progression. To support AD drug development, we provide key target proteins like APOE, TREM2, Aβ, and Tau, essential for advancing therapeutic strategies for AD.

Harnessing iPSC-derived organoid technology presents immense potential in biomedical research, particularly in toxicity testing, disease modeling, personalized medicine, and regenerative medicine. We offer comprehensive organoid solutions to support your exploration of these applications. Our detailed protocol videos guide you through every step of the organoid differentiation process, from initial cell culture to the formation and identification of mature organoids, ensuring a smooth and effective workflow for your research.